Literature DB >> 26438113

To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.

Stanley Lipkowitz1, Elise C Kohn2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26438113      PMCID: PMC7444335          DOI: 10.1200/JCO.2015.63.6670

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival.

Authors:  M Ursic-Vrscaj; S Bebar; M P Zakelj
Journal:  Menopause       Date:  2001 Jan-Feb       Impact factor: 2.953

2.  Relative contributions of aging and estrogen deficiency to postmenopausal bone loss.

Authors:  L S Richelson; H W Wahner; L J Melton; B L Riggs
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

3.  Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting.

Authors:  J Coope; J M Thomson; L Poller
Journal:  Br Med J       Date:  1975-10-18

4.  Prospective trial of oestrogen and calcium in postmenopausal women.

Authors:  A Horsman; J C Gallagher; M Simpson; B E Nordin
Journal:  Br Med J       Date:  1977-09-24

5.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Authors:  Rowan T Chlebowski; Garnet L Anderson; Margery Gass; Dorothy S Lane; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Marcia L Stefanick; Judith Ockene; Gloria E Sarto; Karen C Johnson; Jean Wactawski-Wende; Peter M Ravdin; Robert Schenken; Susan L Hendrix; Aleksandar Rajkovic; Thomas E Rohan; Shagufta Yasmeen; Ross L Prentice
Journal:  JAMA       Date:  2010-10-20       Impact factor: 56.272

6.  Hormone replacement therapy and prognosis in ovarian cancer patients.

Authors:  Alexander Hein; Falk C Thiel; Christian M Bayer; Peter A Fasching; Lothar Häberle; Michael P Lux; Stefan P Renner; Sebastian M Jud; Michael G Schrauder; Andreas Müller; David Wachter; Johanna Strehl; Arndt Hartmann; Matthias W Beckmann; Claudia Rauh
Journal:  Eur J Cancer Prev       Date:  2013-01       Impact factor: 2.497

Review 7.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

8.  Hormone replacement therapy and survival after surgery for ovarian cancer.

Authors:  R A Eeles; S Tan; E Wiltshaw; I Fryatt; R P A'Hern; J H Shepherd; C L Harmer; P R Blake; C E Chilvers
Journal:  BMJ       Date:  1991-02-02

9.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Authors:  Weiva Sieh; Martin Köbel; Teri A Longacre; David D Bowtell; Anna deFazio; Marc T Goodman; Estrid Høgdall; Suha Deen; Nicolas Wentzensen; Kirsten B Moysich; James D Brenton; Blaise A Clarke; Usha Menon; C Blake Gilks; Andre Kim; Jason Madore; Sian Fereday; Joshy George; Laura Galletta; Galina Lurie; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Rayna K Matsuno; Susanne Krüger Kjær; Allan Jensen; Claus Høgdall; Kimberly R Kalli; Brooke L Fridley; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Louise A Brinton; Hannah P Yang; Mark E Sherman; Montserrat García-Closas; Jolanta Lissowska; Kunle Odunsi; Carl Morrison; Shashikant Lele; Wiam Bshara; Lara Sucheston; Mercedes Jimenez-Linan; Kristy Driver; Jennifer Alsop; Marie Mack; Valerie McGuire; Joseph H Rothstein; Barry P Rosen; Marcus Q Bernardini; Helen Mackay; Amit Oza; Eva L Wozniak; Elizabeth Benjamin; Aleksandra Gentry-Maharaj; Simon A Gayther; Anna V Tinker; Leah M Prentice; Christine Chow; Michael S Anglesio; Sharon E Johnatty; Georgia Chenevix-Trench; Alice S Whittemore; Paul D P Pharoah; Ellen L Goode; David G Huntsman; Susan J Ramus
Journal:  Lancet Oncol       Date:  2013-07-09       Impact factor: 41.316

10.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

View more
  1 in total

1.  Hormone replacement therapy after surgery for epithelial ovarian cancer.

Authors:  Nungrutai Saeaib; Krantarat Peeyananjarassri; Tippawan Liabsuetrakul; Rakchai Buhachat; Eva Myriokefalitaki
Journal:  Cochrane Database Syst Rev       Date:  2020-01-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.